- Home
- VIGL vs CEE Comparison
VIGL vs CEE Comparison
Compare VIGL & CEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- CEE
- Stock Information
- Founded
- VIGL 2020
- CEE 1990
- Country
- VIGL United States
- CEE Germany
- Employees
- VIGL N/A
- CEE N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- CEE Finance Companies
- Sector
- VIGL Health Care
- CEE Finance
- Exchange
- VIGL Nasdaq
- CEE Nasdaq
- Market Cap
- VIGL 89.3M
- CEE 72.9M
- IPO Year
- VIGL 2022
- CEE N/A
- Fundamental
- Price
- VIGL $3.03
- CEE $13.82
- Analyst Decision
- VIGL Strong Buy
- CEE
- Analyst Count
- VIGL 5
- CEE 0
- Target Price
- VIGL $21.00
- CEE N/A
- AVG Volume (30 Days)
- VIGL 642.5K
- CEE 22.0K
- Earning Date
- VIGL 03-25-2025
- CEE 01-01-0001
- Dividend Yield
- VIGL N/A
- CEE 3.86%
- EPS Growth
- VIGL N/A
- CEE N/A
- EPS
- VIGL N/A
- CEE N/A
- Revenue
- VIGL N/A
- CEE N/A
- Revenue This Year
- VIGL N/A
- CEE N/A
- Revenue Next Year
- VIGL N/A
- CEE N/A
- P/E Ratio
- VIGL N/A
- CEE N/A
- Revenue Growth
- VIGL N/A
- CEE N/A
- 52 Week Low
- VIGL $1.49
- CEE $7.80
- 52 Week High
- VIGL $6.06
- CEE $10.32
- Technical
- Relative Strength Index (RSI)
- VIGL 77.87
- CEE 74.56
- Support Level
- VIGL $2.71
- CEE $15.01
- Resistance Level
- VIGL $2.95
- CEE $16.71
- Average True Range (ATR)
- VIGL 0.21
- CEE 0.70
- MACD
- VIGL 0.03
- CEE 0.16
- Stochastic Oscillator
- VIGL 86.18
- CEE 66.26
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
About CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.